Chemotherapy-related amenorrhea (CRA) after adjuvant ado-trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH) (TBCRC033: ATEMPT Trial).
Kathryn J RuddyYue ZhengNabihah TayobJiani HuChau T DangDenise A YardleySteven J IsakoffVicente V ValeroMeredith G FaggenTherese M MulveyRon BoseTal SellaDouglas J WecksteinAntonio C WolffKatherine E Reeder-HayesHope S RugoBhuvaneswari RamaswamyDan S ZuckermanLowell L HartVijayakrishna K GadiMichael ConstantineKit L ChengFrederick M BriccettiBryan P SchneiderA Merrill GarrettP Kelly MarcomKathy S AlbainPatricia A DeFuscoNadine M TungBlair M ArdmanRita NandaRachel C JankowitzMothaffar RimawiVandana AbramsonPaula R PohlmannCatherine Van PoznakAndres Forero-TorresMinetta C LiuShoshana RosenbergMichelle K DeMeoHarold J BursteinEric P WinerIan E KropAnn H PartridgeSara M TolaneyPublished in: Breast cancer research and treatment (2021)
Amenorrhea at 18 months was less likely in recipients of adjuvant T-DM1 than TH. Future studies are needed to understand how T-DM1 impacts risk of infertility and permanent menopause, and to assess amenorrhea rates when T-DM1 is administered after standard HER2-directed chemotherapy regimens.
Keyphrases
- metastatic breast cancer
- early stage
- epidermal growth factor receptor
- locally advanced
- clinical trial
- phase iii
- randomized controlled trial
- current status
- squamous cell carcinoma
- postmenopausal women
- radiation therapy
- phase ii
- metabolic syndrome
- insulin resistance
- polycystic ovary syndrome
- skeletal muscle
- kidney transplantation
- drug induced